Giancarlo Comi Selected Research

teriflunomide

11/2020	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
10/2020	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
1/2020	Ofatumumab versus Teriflunomide in Multiple Sclerosis.
1/2020	Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
8/2019	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.
1/2018	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
5/2016	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.
3/2016	Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
1/2016	Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
10/2014	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giancarlo Comi Research Topics

Disease

158	Multiple Sclerosis 11/2022 - 04/2003
42	Relapsing-Remitting Multiple Sclerosis 10/2022 - 03/2006
14	Inflammation (Inflammations) 02/2022 - 12/2002
13	Disease Progression 11/2019 - 06/2003
12	Stroke (Strokes) 07/2021 - 08/2008
12	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 02/2003
11	COVID-19 07/2022 - 01/2020
11	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 06/2003
11	Atrophy 01/2020 - 06/2005
10	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 05/2004
9	Infections 01/2022 - 02/2010
8	Optic Neuritis (Retrobulbar Neuritis) 12/2021 - 04/2016
7	Progressive Multifocal Leukoencephalopathy 02/2022 - 01/2014
7	Neuroinflammatory Diseases 01/2021 - 03/2009
6	Ischemic Stroke 01/2021 - 01/2009
6	Parkinson Disease (Parkinson's Disease) 01/2020 - 03/2013
6	Cognitive Dysfunction 01/2020 - 11/2010
6	Neoplasms (Cancer) 04/2019 - 01/2013
6	Dementia (Dementias) 01/2019 - 01/2016
6	Migraine Disorders (Migraine) 10/2016 - 05/2008
5	Fatigue 12/2018 - 11/2002
5	Headache (Headaches) 04/2016 - 05/2008
5	Epilepsy (Aura) 02/2016 - 11/2012
4	Lymphopenia (Lymphocytopenia) 01/2020 - 02/2010
4	Pain (Aches) 12/2018 - 09/2013
4	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2018 - 10/2009
4	Chronic Progressive Multiple Sclerosis 10/2017 - 09/2004
4	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 03/2017 - 04/2012
3	Macular Edema 06/2021 - 02/2010
3	Spontaneous Abortion (Miscarriage) 01/2020 - 10/2012
3	Atrioventricular Block 11/2019 - 02/2010
3	Herpes Zoster 04/2019 - 02/2010
3	Brain Diseases (Brain Disorder) 01/2019 - 10/2008
3	Polyneuropathies (Polyneuropathy) 01/2019 - 12/2007
3	Frontotemporal Dementia (Semantic Dementia) 01/2017 - 01/2012
3	Primary Progressive Aphasia 01/2015 - 01/2012
3	Pathologic Processes 08/2014 - 12/2011
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 02/2015
2	Ganglion Cysts (Ganglion) 12/2021 - 01/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2021 - 12/2017
2	Opportunistic Infections (Opportunistic Infection) 11/2019 - 04/2019
2	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2019 - 10/2009
2	Immune Reconstitution Inflammatory Syndrome 01/2019 - 01/2014
2	Dyskinesias (Dyskinesia) 12/2017 - 03/2013
2	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 05/2017 - 11/2003

Drug/Important Bio-Agent (IBA)

24	Biomarkers (Surrogate Marker)IBA 12/2021 - 06/2005
21	Fingolimod Hydrochloride (FTY720)FDA Link 10/2022 - 09/2006
20	Natalizumab (Tysabri)FDA Link 11/2022 - 10/2009
18	InterferonsIBA 11/2021 - 06/2003
17	Interferon-betaIBA 01/2022 - 05/2005
17	Cladribine FDA LinkGeneric 11/2021 - 02/2010
16	teriflunomideIBA 11/2020 - 10/2011
15	Glatiramer Acetate (Copaxone)FDA Link 11/2021 - 11/2002
14	TabletsIBA 01/2021 - 02/2010
13	Interferon beta-1a FDA Link 01/2022 - 10/2004
12	Pharmaceutical PreparationsIBA 01/2021 - 10/2004
8	ozanimodIBA 10/2022 - 04/2016
7	laquinimodIBA 04/2022 - 01/2012
7	ocrelizumabIBA 01/2022 - 01/2017
7	Alemtuzumab (Campath)FDA Link 01/2022 - 01/2020
7	AntibodiesIBA 01/2022 - 07/2003
6	Retinaldehyde (Retinal)IBA 12/2021 - 05/2016
6	Oligoclonal BandsIBA 12/2021 - 01/2004
6	GadoliniumIBA 12/2021 - 11/2012
5	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 05/2004
5	Messenger RNA (mRNA)IBA 10/2021 - 05/2004
5	Interferon beta-1b (Betaseron)FDA Link 12/2017 - 10/2009
5	Proteins (Proteins, Gene)FDA Link 05/2017 - 01/2004
4	Sphingosine-1-Phosphate ReceptorsIBA 06/2021 - 04/2016
4	nabiximols (Sativex)IBA 01/2019 - 11/2015
4	Immunologic Factors (Immunomodulators)IBA 01/2018 - 09/2014
4	frovatriptan (Allegro)FDA Link 01/2017 - 08/2014
4	Amyloid (Amyloid Fibrils)IBA 01/2017 - 02/2003
4	Alanine Transaminase (SGPT)IBA 01/2017 - 03/2014
4	Mitoxantrone (Novantrone)FDA LinkGeneric 05/2013 - 09/2008
3	Rituximab (Mabthera)FDA Link 11/2021 - 05/2017
3	siponimodIBA 11/2021 - 01/2020
3	IronIBA 11/2015 - 01/2010
3	Intravenous Immunoglobulins (IVIG)FDA Link 12/2010 - 11/2003
3	Protons (Proton)IBA 10/2009 - 06/2003
2	Methylprednisolone FDA LinkGeneric 07/2022 - 01/2021
2	VaccinesIBA 04/2022 - 01/2020
2	Complement System Proteins (Complement)IBA 02/2022 - 09/2013
2	nitazoxanide (NTZ)FDA Link 02/2022 - 03/2015
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 08/2013
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 01/2019
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 10/2015
2	salicylhydroxamic acid (SHAM)IBA 01/2020 - 11/2013
2	CannabinoidsIBA 01/2019 - 11/2012
2	CytokinesIBA 01/2018 - 05/2004
2	SuspensionsIBA 01/2018 - 11/2015
2	DNA-Binding Proteins (DNA Binding Protein)IBA 03/2017 - 01/2014

Therapy/Procedure

60	Therapeutics 04/2022 - 02/2003
9	Transcranial Magnetic Stimulation 07/2021 - 05/2013
5	Transplantation 11/2017 - 08/2009
4	Injections 07/2020 - 07/2013
3	Neurological Rehabilitation 02/2022 - 01/2016
3	Hematopoietic Stem Cell Transplantation 01/2021 - 03/2014
3	Wearable Electronic Devices 07/2020 - 07/2019
3	Stem Cell Transplantation 11/2017 - 06/2005